An emergency use authorization has been requested for ‘Molnupiravir’, the pill developed with the collaboration of Merck and Ridgeback Biotherapeutics. In accordance with the results of the phase 3 clinical trials of the pill, it has been announced that the risk of hospitalization of those who have coronavirus is reduced by half. As a result, it is stated that an emergency use authorization has been requested from the FDA.
Please click for detailed information.
https://gazetekarinca.com/covid-19u-onçiler-oral-hap-icin-izin-basvurusu-yapildi/
